Please enter exact key words
A Novel Anti-LAG3 Monoclonal Antibody

With Immunomodulating and Antineoplastic Activities

Home / Available Projects / A Novel Anti-LAG3 Monoclonal Antibody

A Novel Anti-LAG3 Monoclonal Antibody

  • Overview
  • Target
  • Drug Modality
  • Indication
  • Mechanism of Action
  • Status
  • Data
Drug Name Anti-LAG3 monoclonal antibody (mAb)

Anti-LAG3 mAb is a monoclonal antibody targets lymphocyte activating 3 (LAG3) that involves in T cell immune regulation. Anti-LAG3 mAb as an antagonistic antibody removes LAG3 mediated T cell inhibition to make nonspecific immune activation, for the treatment of various solid tumors and hematologic cancers.

Anti-LAG3 mAb differs from the leading competitor (monoclonal antibody 25F7 from Bristol Myers Squibb) with different epitope and higher affinity. Its optimal safety and efficacy can ensure its market share.

Target Lymphocyte activating 3 (LAG3)
Drug Modality Antibody
Indication Solid tumor; hematologic malignancies
Product Category Immune checkpoint inhibitor
Mechanism of Action Counteracting the inhibitory activity of LAG3 to enhance T cell activation against tumor growth
Status Preclinical
Patent Patent application in preparation

Collaboration Opportunity

Actively seeking partnership (flexible with collaboration structures).

We look forward to hearing from you.

Lymphocyte Activating 3 (LAG3)

Introduction LAG3 protein belongs to Ig superfamily and contains 4 extracellular Ig-like domains. LAG3 is an inhibitory receptor on antigen activated T-cells. Upon binding to ligands, LAG3 delivers Inhibitory signals. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. LAG3 negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. LAG3 is constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. LAG3 also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation.
Approved Name Lymphocyte activating 3
Official Symbol LAG3
Gene Type Protein coding
Synonyms CD223
Ensembl ENSG00000089692
Gene ID 3902
mRNA Refseq NM_002286
Protein Refseq NP_002277.4
OMIM 153337
UniProt ID P18627
Chromosome Location 12p13.31

Clinical Resources

Gene Function The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. Expression of LAG3 gene was undetectable in resting peripheral blood lymphocytes, whereas it was found in activated T and NK cells.
Pathway NF-kappaB Signaling; class I MHC mediated antigen processing and presentation; MHC class II antigen presentation
Major Conditions Smoldering myeloma; kyphoscoliotic heart disease; age-related macular degeneration; renal cell carcinoma

Monoclonal Antibody

Anti-LAG3 mAb is a monoclonal antibody binding to a unique epitope of LAG3 with high safety and efficacy. This antibody is developed for the treatment of multiple cancers in combination with other immune check point inhibitors. The combination therapy will have smaller safety window, especially with those primary activators or immune inhibitors.

Solid Tumor

Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant. Different types of solid tumors are named for the type of cells that form them, such as breast cancer. Cancer deaths are projected to rise, with an estimate of 11.4 million people dying from cancer in 2030.

The best strategy for fighting cancer is to reduce cancer risk. Nevertheless, even if applying all that are known so far about cancer prevention, one out of four cancers would still occur. Because of this, therapies that target malignancies after they have developed will continue to be important for some time to come. The most commonly used treatment modalities of cancer include some combination of surgery, radiation therapy, and chemotherapy. The best approach to treating cancer provides a balance between therapeutic effectiveness and minimization of treatment-associated side effects.

The global market for solid tumor treatment was estimated at $121.3 billion in 2018 and is expected to reach $424.6 billion by 2027, expanding at a CAGR of 15% from 2019 to 2027.

Hematologic Malignancies

Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia, myeloma, and lymphoma.

Leukemia is a heterogeneous class of malignant diseases of the bone marrow and blood that is characterized by the uncontrolled proliferation of undifferentiated hematopoietic cells. According to Globocan data for 2018, the global incidence of leukemia was 437,033 in 2018, and the number of deaths worldwide due to leukemia was 309,006.

Lymphomas is a class of hematologic malignancies originating in lymphocytes, typically in lymph nodes. Lymphomas are subdivided into two major categories: Hodgkin’s Lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). The latter accounts for approximately 90% of all lymphomas. In 2018, the International Agency for Research on Cancer (IARC) estimates that there were 284,713 cases of NHL diagnosed in men and 224,877 in women worldwide.

Myeloma is a B cell-dependent hematological malignancy caused by excessive clonal proliferation of terminally differentiated plasma cells in bone marrow. According to the Global Burden of Disease study, approximately 154,000 new cases of multiple myeloma were diagnosed worldwide in 2015 and an estimated 101,100 deaths.

The global therapeutics market size of hematologic malignancies was valued at $40.4 billion in 2017 and is anticipated to reach $87.0 billion by 2025.

Counteracting the Inhibitory Activity of LAG3 to Enhance T Cell Activation Against Tumor Growth

LAG3 is a surface molecule located closely to CD4. The human LAG3 gene is 20% identical to the human CD4 gene. Like CD4, LAG3 binds to major histocompatibility complex-II (MHC-II) on antigen-presenting cells (APCs), but with stronger affinity. LAG3 interacts with MHC-II to inhibit the binding of the same MHC molecule to TCR and CD4, thus directly hindering TCR signaling in immune response. Crosslinking of LAG3 and CD3 can impair T cell proliferation and cytokine secretion by inhibiting calcium ion fluxes. Besides, the LAG3/MHC-II interaction may also act as bidirectional inhibitory signaling shared by immune cells and tumor cells. Meanwhile, LAG3-expressing Tregs may utilize an immune tyrosine-based activation motif (ITAM)-modulated suppressive signaling pathway to indirectly inhibit the function of dendritic cells.

Based on the immunomodulatory role of LAG3 on T cell function in cancer, anti-LAG3 mAb binds to LAG3 to block the interaction between LAG3 and MHCII for removing LAG3 mediated T cell inhibition. Activating T cells and enhancing cytotoxic T-cell-mediated tumor cell lysis leads to a reduction in tumor growth.

Figure. Targeting effector and regulatory T cells with LAG3 antagonistic antibodies and
activating antigen presenting cells with soluble LAG3-Ig
Cancers (Basel). 2019 Aug; 11(8): 1213.

The Status of Anti-LAG3 mAb

Complete preclinical package is available. Ready for mass production and clinical trials.

Data Available Upon Request

Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.